- Conditions
- Prostate Cancer
- Interventions
- docetaxel, leuprolide acetate, radiation therapy
- Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Raleigh, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 45
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Interventions
- Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
- Conditions
- Prostate Cancer
- Interventions
- Flutamide, Leuprolide Acetate
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Infertility, Diminished Ovarian Reserve, IVF
- Interventions
- Timing of injectable gonadotropins
- Procedure
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 20 Years to 45 Years · Female only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Manhasset, New York
- Conditions
- Prostate Cancer
- Interventions
- ADT, Enzalutamide, Talazoparib, Degarelix, Luprolide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma
- Interventions
- Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Delayed Puberty, Precocious Puberty
- Interventions
- Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Interventions
- Abiraterone Acetate, Bicalutamide, Degarelix, Flutamide, Goserelin Acetate, Leuprolide Acetate, Nilutamide, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darolutamide, Leuprolide Acetate, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 27
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 21 more
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, Leuprolide, Prednisone, Abiraterone Acetate
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- La Jolla, California • Boston, Massachusetts • New York, New York
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Interventions
- sipuleucel-T, leuprolide acetate
- Biological · Drug
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 14
- States / cities
- Homewood, Alabama • La Jolla, California • Los Angeles, California + 7 more
- Conditions
- Prostate Cancer
- Interventions
- Trelstar, Lupron, Zoladex
- Drug
- Lead sponsor
- Pharmatech
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 11
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Fresno, California + 7 more
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Interventions
- Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Durham, North Carolina + 2 more
- Conditions
- Prostate Cancer
- Interventions
- ARN-509, LHRH Agonist
- Drug
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 2 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Placebo, Eligard 22.5Mg Suspension for Injection
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years to 120 Years · Female only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Boca Raton, Florida • New York, New York • Madison, Wisconsin
- Conditions
- Prostate Cancer
- Interventions
- DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coronary Heart Disease
- Interventions
- Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Casodex, Eulexin, LHRH agonist, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 1,579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2022
- U.S. locations
- 241
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more
- Conditions
- Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Interventions
- Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
- Drug · Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 311
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Docetaxel, Leuprolide, Bicalutamide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
- Drug · Radiation · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Interventions
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate, GNRH-A Goserelin, Degarelix
- Drug
- Lead sponsor
- Praful Ravi, MB BCHir, MRCP
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts